Literature DB >> 28256027

Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS-p study.

E B Cunningham1, B Hajarizadeh1, N A Bretana1,2, J Amin1, B Betz-Stablein2, G J Dore1, F Luciani1,2, S Teutsch2, K Dolan3, A R Lloyd1,2, J Grebely1.   

Abstract

Hepatitis C virus (HCV) transmission is high in prisons. This study investigated trends in HCV incidence and associated factors among a cohort of prisoners with a history of injecting drug use in New South Wales, Australia. Data were available from the Hepatitis C Incidence and Transmission Study-prisons (HITS-p) from 2005 to 2014. Temporal trends in HCV incidence were evaluated. Factors associated with time to HCV seroconversion among people with ongoing injecting was assessed using Cox proportional hazards. Among 320 antibody-negative participants with a history of injecting drug use (mean age 26; 72% male), 62% (n=197) reported injecting drug use during follow-up. Overall, 93 infections were observed. HCV incidence was 11.4/100 person-years in the overall population and 6.3/100 person-years among the continually imprisoned population. A stable trend in HCV incidence was observed. Among the overall population with ongoing injecting during follow-up, ≥weekly injecting drug use frequency was independently associated with time to HCV seroconversion. Among continuously imprisoned injectors with ongoing injecting during follow-up, needle/syringe sharing was independently associated with time to HCV seroconversion. This study demonstrates that prison is a high-risk environment for acquisition of HCV infection. Needle and syringe sharing was associated with HCV infection among continually imprisoned participants, irrespective of frequency of injecting or the type of drug injected. These findings highlight the need for the evaluation of improved HCV prevention strategies in prison, including needle/syringe programmes and HCV treatment.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990PWIDzzm321990; Australia; hepatitis C Virus; incidence; prison

Mesh:

Year:  2017        PMID: 28256027     DOI: 10.1111/jvh.12701

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  17 in total

1.  HIV and Viral Hepatitis Among Imprisoned Key Populations.

Authors:  Andrea L Wirtz; Ping T Yeh; Natalie L Flath; Chris Beyrer; Kate Dolan
Journal:  Epidemiol Rev       Date:  2018-06-01       Impact factor: 6.222

2.  The Impact of Medications for Opioid Use Disorder on Hepatitis C Incidence Among Incarcerated Persons: A Systematic Review.

Authors:  Nikhil Seval; Alysse Wurcel; Craig G Gunderson; Alyssa Grimshaw; Sandra A Springer
Journal:  Infect Dis Clin North Am       Date:  2020-09       Impact factor: 5.982

3.  Facilitating treatment of HCV in primary care in regional Australia: closing the access gap.

Authors:  Lauren White; Ali Azzam; Lauren Burrage; Clare Orme; Barbara Kay; Sarah Higgins; Simone Kaye; Andrew Sloss; Jennifer Broom; Nicola Weston; Jonathan Mitchell; James O'Beirne
Journal:  Frontline Gastroenterol       Date:  2018-10-24

4.  Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there?

Authors:  Jason Grebely; Gregory J Dore; Sébastien Morin; Jürgen K Rockstroh; Marina B Klein
Journal:  J Int AIDS Soc       Date:  2017-07-28       Impact factor: 5.396

Review 5.  Population Health and Cost-Effectiveness Implications of a "Treat All" Recommendation for HCV: A Review of the Model-Based Evidence.

Authors:  Lauren E Cipriano; Jeremy D Goldhaber-Fiebert
Journal:  MDM Policy Pract       Date:  2018-05-24

6.  Understanding the Determinants of BnAb Induction in Acute HCV Infection.

Authors:  Alexander P Underwood; Melanie R Walker; Nicholas A Brasher; Auda A Eltahla; Lisa Maher; Fabio Luciani; Andrew R Lloyd; Rowena A Bull
Journal:  Viruses       Date:  2018-11-21       Impact factor: 5.048

7.  Barriers and facilitators to hepatitis C (HCV) screening and treatment-a description of prisoners' perspective.

Authors:  Des Crowley; Marie Claire Van Hout; John S Lambert; Enda Kelly; Carol Murphy; Walter Cullen
Journal:  Harm Reduct J       Date:  2018-12-11

8.  The seroprevalence of untreated chronic hepatitis C virus (HCV) infection and associated risk factors in male Irish prisoners: a cross-sectional study, 2017.

Authors:  Desmond Crowley; John S Lambert; Graham Betts-Symonds; Walter Cullen; Mary Keevans; Enda Kelly; Eamon Laird; Tina McHugh; Susan McKiernan; Sarah Jayne Miggin; Carol Murphy; Ross Murtagh; Deirdre O'Reilly; Ciara Tobin; Marie Claire Van Hout
Journal:  Euro Surveill       Date:  2019-04

9.  Optimized cell systems for the investigation of hepatitis C virus E1E2 glycoproteins.

Authors:  Mphatso D Kalemera; Joan Capella-Pujol; Ana Chumbe; Alexander Underwood; Rowena A Bull; Janke Schinkel; Kwinten Sliepen; Joe Grove
Journal:  J Gen Virol       Date:  2021-01       Impact factor: 3.891

10.  A policy analysis exploring hepatitis C risk, prevention, testing, treatment and reinfection within Australia's prisons.

Authors:  Lise Lafferty; T Cameron Wild; Jake Rance; Carla Treloar
Journal:  Harm Reduct J       Date:  2018-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.